Session (CTI)

Health technology assessment (HTA) is a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle, with the goal of informing decisions that promote an equitable, efficient, and high-quality health system. By systematically assessing clinical benefit, comparative effectiveness, and real-world impact, HTA ensures that coverage, reimbursement, and resource allocation decisions are informed by evidence, context, and patient need, rather than price alone. Despite its central role in healthcare decision making, the value and application of HTA remain the subject of ongoing debate among different stakeholders including policymakers and health technology developers. Globally, HTA is applied across a wide range of decision contexts beyond pricing, including priority setting, reimbursement, and procurement. On 8 November 2026, ISPOR convened its first in person Global HTA Roundtable, bringing together 90 participants from 59 countries and jurisdictions to explore areas of consensus on the value of HTA and how it can be used most effectively across health systems. In this session, organized by the ISPOR HTA Council, attendees will hear from three HTA bodies or payers who participated in the Roundtable and will share their perspectives on the importance of global collaboration and key takeaways from the discussion. The session will conclude with an open audience discussion, providing participants with the opportunity to ask questions and share their own experiences and insights.